Inflation Trends and Federal Reserve Policy: As a clinical-stage biotechnology company, Allogene Therapeutics relies heavily on external funding for its research and development. Persistent inflation and potential hawkish stances from the Federal Reserve, indicated by FOMC minutes and CPI data, could lead to higher interest rates, increasing borrowing costs and potentially dampening investor appetite for growth stocks that are not yet profitable.

Geopolitical Instability and Risk-Off Sentiment: Ongoing geopolitical conflicts, such as those in the Middle East, contribute to global uncertainty and oil price volatility. This can foster a 'risk-off' environment among investors, leading to a shift away from more speculative assets like clinical-stage biotech stocks, which could negatively impact ALLO's valuation and capital-raising efforts.

Capital Availability for Growth-Oriented Sectors: Closely tied to inflation and interest rates, a tighter capital market due to aggressive monetary tightening by the Fed could make it more challenging for companies like Allogene Therapeutics, which require significant and consistent investment for R&D, to secure necessary funding or may lead to less favorable financing terms.